JN Nova Pharma

Profile

JN Nova Pharma is a Canadian biotechnology company developing a proprietary platform technology to address multiple high-value unmet medical needs, including acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF), Acute Kidney Injury (AKI).

It has received, Health Canada authorization to initiate its first-in-human clinical trial and will commence the Phase IA/B clinical study in Q4 2026. At Bio Europe, its interested in identifying co-development parters.

JN Nova Pharma logo

Website

jnnova.com

Contact


Event details

Date: November 9 - 11, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

25 in total